Efruxifermin for NASH/MASH with liver scarring
Part of Digestive system, Hormones & metabolism clinical trials.
This study tests a new medicine, efruxifermin, for people with NASH/MASH (fatty liver disease) and moderate liver scarring. It aims to see if the drug can help improve the liver's condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 80 years old.
- You need to have NASH (nonalcoholic steatohepatitis) or MASH with moderate liver scarring (stage 2 or 3 fibrosis) confirmed by a recent liver biopsy.
- You must have a metabolic issue—like obesity, high blood pressure, abnormal cholesterol, or high blood sugar—or have type 2 diabetes.
- You cannot have cirrhosis (stage 4 fibrosis) or another liver disease.
- If you have diabetes, it must be well-controlled (type 2) and not type 1 diabetes.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if the heart medication digoxin can help people with NASH (fatty liver disease with inflammation), who have moderate liver scarring. You will receive digoxin or a placebo for 24 weeks and have a liver biopsy before and after treatment to see if the medication reduces liver damage.
This study tests a new medication called efruxifermin for people with cirrhosis (liver scarring) caused by NASH, a type of fatty liver disease. The goal is to see if the drug can help improve liver health and prevent further damage.
This trial tests an experimental drug called pegozafermin to see if it can help people with MASH (a fatty liver disease) and liver scarring (fibrosis). It's for people who have moderate-to-advanced scarring but not cirrhosis, and who have not had other serious liver conditions or poorly controlled diabetes.
This trial tests a new drug called pegozafermin to see if it can help people with cirrhosis (scarring) of the liver caused by MASH (a fatty liver disease). If you have cirrhosis and either diabetes or multiple risk factors, this study might be an option for you.
This trial tests an investigational drug called survodutide for people with NASH or MASH, a type of fatty liver disease that also has liver scarring (moderate or advanced fibrosis). The goal is to see if the drug can improve the condition.
This trial tests a new medicine called Efimosfermin Alfa for people with MASH (a fatty liver disease) and moderate liver scarring. It aims to see if the medicine can improve the liver condition.
Hear when a new NASH With Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.